JP2018527570A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018527570A5 JP2018527570A5 JP2018511233A JP2018511233A JP2018527570A5 JP 2018527570 A5 JP2018527570 A5 JP 2018527570A5 JP 2018511233 A JP2018511233 A JP 2018511233A JP 2018511233 A JP2018511233 A JP 2018511233A JP 2018527570 A5 JP2018527570 A5 JP 2018527570A5
- Authority
- JP
- Japan
- Prior art keywords
- peripheral blood
- cells
- positive
- combination
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000000034 method Methods 0.000 claims description 110
- 210000004027 cell Anatomy 0.000 claims description 67
- 239000011886 peripheral blood Substances 0.000 claims description 51
- 210000005259 peripheral blood Anatomy 0.000 claims description 46
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 claims description 45
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 claims description 45
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 35
- 206010028980 Neoplasm Diseases 0.000 claims description 30
- 201000011510 cancer Diseases 0.000 claims description 30
- 239000003814 drug Substances 0.000 claims description 29
- 229940124597 therapeutic agent Drugs 0.000 claims description 29
- 239000002458 cell surface marker Substances 0.000 claims description 24
- 210000001185 bone marrow Anatomy 0.000 claims description 23
- INVTYAOGFAGBOE-UHFFFAOYSA-N entinostat Chemical compound NC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1CNC(=O)OCC1=CC=CN=C1 INVTYAOGFAGBOE-UHFFFAOYSA-N 0.000 claims description 23
- 229950005837 entinostat Drugs 0.000 claims description 23
- 238000002648 combination therapy Methods 0.000 claims description 19
- 239000011230 binding agent Substances 0.000 claims description 11
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 claims description 9
- 206010006187 Breast cancer Diseases 0.000 claims description 9
- 208000026310 Breast neoplasm Diseases 0.000 claims description 9
- 229960000255 exemestane Drugs 0.000 claims description 9
- 238000001565 modulated differential scanning calorimetry Methods 0.000 claims description 8
- 210000004985 myeloid-derived suppressor cell Anatomy 0.000 claims description 8
- 239000003146 anticoagulant agent Substances 0.000 claims description 6
- 229940127219 anticoagulant drug Drugs 0.000 claims description 6
- 201000001441 melanoma Diseases 0.000 claims description 6
- 238000004393 prognosis Methods 0.000 claims description 6
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 5
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims description 5
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 claims description 5
- 102000006354 HLA-DR Antigens Human genes 0.000 claims description 5
- 108010058597 HLA-DR Antigens Proteins 0.000 claims description 5
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 5
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 claims description 5
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 5
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims description 5
- 238000000684 flow cytometry Methods 0.000 claims description 5
- 201000005202 lung cancer Diseases 0.000 claims description 5
- 208000020816 lung neoplasm Diseases 0.000 claims description 5
- 210000005087 mononuclear cell Anatomy 0.000 claims description 5
- 101150013553 CD40 gene Proteins 0.000 claims description 4
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 claims description 4
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims description 4
- 102100022338 Integrin alpha-M Human genes 0.000 claims description 4
- 206010027480 Metastatic malignant melanoma Diseases 0.000 claims description 4
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims description 4
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 4
- 238000001802 infusion Methods 0.000 claims description 4
- 208000021039 metastatic melanoma Diseases 0.000 claims description 4
- 210000001616 monocyte Anatomy 0.000 claims description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical group OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 3
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 3
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims description 3
- 229960002897 heparin Drugs 0.000 claims description 3
- 229920000669 heparin Polymers 0.000 claims description 3
- 208000027706 hormone receptor-positive breast cancer Diseases 0.000 claims description 3
- 201000009546 lung large cell carcinoma Diseases 0.000 claims description 3
- 201000005243 lung squamous cell carcinoma Diseases 0.000 claims description 3
- 229960003301 nivolumab Drugs 0.000 claims description 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 3
- 229960002621 pembrolizumab Drugs 0.000 claims description 3
- 208000022679 triple-negative breast carcinoma Diseases 0.000 claims description 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 3
- 230000003442 weekly effect Effects 0.000 claims description 3
- 102100035248 Alpha-(1,3)-fucosyltransferase 4 Human genes 0.000 claims description 2
- 101001022185 Homo sapiens Alpha-(1,3)-fucosyltransferase 4 Proteins 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 18
- 238000002560 therapeutic procedure Methods 0.000 claims 4
- 238000005259 measurement Methods 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021173852A JP7206352B2 (ja) | 2015-09-02 | 2021-10-25 | 併用療法のための患者の選択 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562213288P | 2015-09-02 | 2015-09-02 | |
| US62/213,288 | 2015-09-02 | ||
| US201562219612P | 2015-09-16 | 2015-09-16 | |
| US62/219,612 | 2015-09-16 | ||
| PCT/US2016/050274 WO2017041043A1 (en) | 2015-09-02 | 2016-09-02 | Selection of patients for combination therapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021173852A Division JP7206352B2 (ja) | 2015-09-02 | 2021-10-25 | 併用療法のための患者の選択 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018527570A JP2018527570A (ja) | 2018-09-20 |
| JP2018527570A5 true JP2018527570A5 (enExample) | 2019-12-12 |
Family
ID=58188549
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018511233A Withdrawn JP2018527570A (ja) | 2015-09-02 | 2016-09-02 | 併用療法のための患者の選択 |
| JP2021173852A Active JP7206352B2 (ja) | 2015-09-02 | 2021-10-25 | 併用療法のための患者の選択 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021173852A Active JP7206352B2 (ja) | 2015-09-02 | 2021-10-25 | 併用療法のための患者の選択 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11397184B2 (enExample) |
| EP (1) | EP3345002A4 (enExample) |
| JP (2) | JP2018527570A (enExample) |
| KR (2) | KR20240017973A (enExample) |
| CN (2) | CN108139403B (enExample) |
| AU (2) | AU2016318136B2 (enExample) |
| BR (1) | BR112018003238A2 (enExample) |
| CA (1) | CA2994731C (enExample) |
| HK (1) | HK1258128A1 (enExample) |
| IL (1) | IL257355B (enExample) |
| MX (1) | MX2018002640A (enExample) |
| RU (1) | RU2018111407A (enExample) |
| WO (1) | WO2017041043A1 (enExample) |
| ZA (1) | ZA201800931B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL254529B2 (en) * | 2015-03-20 | 2024-05-01 | Syndax Pharmaceuticals Inc | Combination of hdac inhibitor and anti-pd-1 antibody for treatment of cancer |
| KR20180104122A (ko) | 2016-01-28 | 2018-09-19 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 | 면역요법을 향상시키기 위한 히스톤 데아세틸라제 저해제의 용도 |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| EP4650005A2 (en) | 2016-07-15 | 2025-11-19 | Viracta Subsidiary, Inc. | Histone deacetylase inhibitors for use in immunotherapy |
| CA3063718A1 (en) | 2017-05-19 | 2018-11-22 | Syndax Pharmaceuticals, Inc. | Combination therapies |
| CA3099702A1 (en) * | 2018-05-07 | 2019-11-14 | Syndax Pharmaceuticals, Inc. | Selection of patients for combination therapy |
| CN109251891B (zh) * | 2018-09-21 | 2021-10-22 | 苏州大学附属第一医院 | 一种cd40联合pd-l1及细胞因子扩增pbmc的方法 |
| CN117054649A (zh) * | 2023-08-04 | 2023-11-14 | 广州中医药大学第一附属医院 | 一种慢性萎缩性胃炎向胃癌转化标志物及其应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4410545A (en) | 1981-02-13 | 1983-10-18 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
| US4328245A (en) | 1981-02-13 | 1982-05-04 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
| US4409239A (en) | 1982-01-21 | 1983-10-11 | Syntex (U.S.A.) Inc. | Propylene glycol diester solutions of PGE-type compounds |
| US6350458B1 (en) | 1998-02-10 | 2002-02-26 | Generex Pharmaceuticals Incorporated | Mixed micellar drug deliver system and method of preparation |
| ITUD20080058A1 (it) * | 2008-03-18 | 2009-09-19 | Thankstem S R L | Kit per la raccolta di sangue, preferibilmente periferico, per la produzione di cellule staminali |
| GB201015765D0 (en) * | 2010-09-21 | 2010-10-27 | Immatics Biotechnologies Gmbh | Use of myeloid cell biomarkers for the diagnosis of cancer |
| CN109517897A (zh) | 2011-04-28 | 2019-03-26 | 南加利福尼亚大学 | 人类髓源抑制性细胞癌症标记 |
| UA123212U (uk) * | 2011-09-02 | 2018-02-26 | Общєство С Огранічєной Отвєтствєностью "Новамедіка" | Спосіб лікування раку молочної залози |
| AU2013290237A1 (en) * | 2012-07-10 | 2015-01-22 | Dana-Farber Cancer Institue, Inc. | Anti-proliferative compounds and uses thereof |
| EP2925301A4 (en) * | 2012-11-29 | 2016-06-01 | Penn State Res Found | THERAPEUTIC PRODUCT AND ANTI-CANCER IMMUNOMODULATOR DHS1P PHOTODYNAMIC |
| AU2015289922A1 (en) * | 2014-07-15 | 2017-02-16 | The Johns Hopkins University | Suppression of myeloid derived suppressor cells and immune checkpoint blockade |
| IL254529B2 (en) | 2015-03-20 | 2024-05-01 | Syndax Pharmaceuticals Inc | Combination of hdac inhibitor and anti-pd-1 antibody for treatment of cancer |
-
2016
- 2016-09-02 EP EP16843146.8A patent/EP3345002A4/en active Pending
- 2016-09-02 BR BR112018003238A patent/BR112018003238A2/pt not_active Application Discontinuation
- 2016-09-02 WO PCT/US2016/050274 patent/WO2017041043A1/en not_active Ceased
- 2016-09-02 US US15/756,898 patent/US11397184B2/en active Active
- 2016-09-02 JP JP2018511233A patent/JP2018527570A/ja not_active Withdrawn
- 2016-09-02 HK HK19100418.3A patent/HK1258128A1/zh unknown
- 2016-09-02 KR KR1020247003086A patent/KR20240017973A/ko not_active Ceased
- 2016-09-02 RU RU2018111407A patent/RU2018111407A/ru unknown
- 2016-09-02 KR KR1020187007043A patent/KR102631377B1/ko active Active
- 2016-09-02 AU AU2016318136A patent/AU2016318136B2/en active Active
- 2016-09-02 CA CA2994731A patent/CA2994731C/en active Active
- 2016-09-02 CN CN201680050875.XA patent/CN108139403B/zh active Active
- 2016-09-02 CN CN202310449867.4A patent/CN116893262A/zh active Pending
- 2016-09-02 MX MX2018002640A patent/MX2018002640A/es unknown
-
2018
- 2018-02-05 IL IL257355A patent/IL257355B/en unknown
- 2018-02-12 ZA ZA2018/00931A patent/ZA201800931B/en unknown
-
2021
- 2021-10-25 JP JP2021173852A patent/JP7206352B2/ja active Active
-
2022
- 2022-03-29 US US17/707,081 patent/US20230061048A1/en not_active Abandoned
- 2022-10-05 AU AU2022246409A patent/AU2022246409A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018527570A5 (enExample) | ||
| Zhu et al. | Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma | |
| Simonaggio et al. | Variation in neutrophil to lymphocyte ratio (NLR) as predictor of outcomes in metastatic renal cell carcinoma (mRCC) and non-small cell lung cancer (mNSCLC) patients treated with nivolumab | |
| de Coaña et al. | Ipilimumab treatment decreases monocytic MDSCs and increases CD8 effector memory T cells in long-term survivors with advanced melanoma | |
| RU2018111407A (ru) | Отбор пациентов для комбинированной терапии | |
| Chihara et al. | Ki-67 is a strong predictor of central nervous system relapse in patients with mantle cell lymphoma (MCL) | |
| Chen et al. | Short leukocyte telomere length predicts poor prognosis and indicates altered immune functions in colorectal cancer patients | |
| Plönes et al. | Serum level of CC-chemokine ligand 18 is increased in patients with non-small-cell lung cancer and correlates with survival time in adenocarcinomas | |
| Markovic et al. | Comparison of prognostic impact of absolute lymphocyte count, absolute monocyte count, absolute lymphocyte count/absolute monocyte count prognostic score and ratio in patients with diffuse large B cell lymphoma | |
| Iriyama et al. | Shorter halving time of BCR‐ABL1 transcripts is a novel predictor for achievement of molecular responses in newly diagnosed chronic‐phase chronic myeloid leukemia treated with dasatinib: Results of the D‐first study of K anto CML study group | |
| Kataoka et al. | Carcinoembryonic antigen as a predictive biomarker of response to nivolumab in non–small cell lung cancer | |
| Sakabe et al. | Expression of cancer stem cell-associated DKK1 mRNA serves as prognostic marker for hepatocellular carcinoma | |
| Lynce et al. | Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study | |
| Lee | Mycosis fungoides and Sézary syndrome | |
| Flörcken et al. | Myeloid-derived suppressor cells in human peripheral blood: optimized quantification in healthy donors and patients with metastatic renal cell carcinoma | |
| Shimura et al. | C-reactive protein is a potential prognostic factor for metastatic gastric cancer | |
| Yumioka et al. | Response to platinum-based chemotherapy rechallenge for patients with pembrolizumab-refractory urothelial carcinoma | |
| Kwon et al. | Clinical features and treatment of collecting duct carcinoma of the kidney from the korean cancer study group genitourinary and gynecology cancer committee | |
| Huffman et al. | Biomarkers of pembrolizumab efficacy in advanced anal squamous cell carcinoma: analysis of a phase II clinical trial and a cohort of long-term responders | |
| Pellegrino et al. | Anti-PD-1-related cryoglobulinemia during treatment with nivolumab in NSCLC patient | |
| Chou et al. | Development and validation of a prognostic score to predict survival in adult patients with solid tumors and bone marrow metastases | |
| Ohmatsu et al. | Primary cutaneous follicular helper T-cell lymphoma treated with allogeneic bone marrow transplantation: immunohistochemical comparison with angioimmunoblastic T-cell lymphoma | |
| Fujiwara et al. | Early serum and hematological responses to pembrolizumab therapy as predictors of survival in metastatic urothelial cancer | |
| Bron et al. | Aging and malignant hemopathies | |
| Hwang et al. | Elevated Neutrophil–to–Lymphocyte Ratio Predicts Survival in Patients with Advanced Gastric Cancer Treated with Trastuzumab Combination Chemotherapy |